1
/
of
2
Influvac (Trivalent Seasonal Inactivated Influenza Split Virion) for IM Injection
Influvac (Trivalent Seasonal Inactivated Influenza Split Virion) for IM Injection
Regular price
₱960.00 PHP
Regular price
Sale price
₱960.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Influvac Trivalent Seasonal Inactivated Influenza Vaccine — Professional-Grade Immunization Solution
Influvac is a clinically proven trivalent seasonal inactivated influenza split virion vaccine formulated for intramuscular injection. This vaccine is designed to provide targeted immunological protection against three circulating influenza strains, making it an essential component of comprehensive seasonal flu prevention programs in clinical and occupational health settings.
The trivalent formulation combines inactivated split virion technology with a carefully selected antigenic composition that aligns with seasonal epidemiological predictions. Each dose is engineered to stimulate robust humoral immune response while maintaining a favorable safety profile across diverse patient populations. The inactivated split virion preparation reduces reactogenicity compared to whole virion vaccines while preserving immunogenic potency.
Influvac is administered via intramuscular injection, typically in the deltoid muscle, with a standard dosing schedule established through rigorous clinical trials. The vaccine is suitable for annual administration as part of seasonal influenza immunization protocols in healthcare facilities, occupational health clinics, and preventive medicine programs.
This product meets international pharmacopeial standards for viral vaccine preparation and is supported by extensive clinical documentation. Healthcare professionals administering Influvac should review complete prescribing information, contraindications, and patient screening requirements prior to injection. Proper cold chain management and storage protocols are essential to maintain vaccine potency.
Influvac represents a trusted option for institutions seeking reliable, data-backed influenza immunization solutions. Consult immunization guidelines and clinical references for patient eligibility, dosing schedules, and post-vaccination monitoring recommendations.
Influvac is a clinically proven trivalent seasonal inactivated influenza split virion vaccine formulated for intramuscular injection. This vaccine is designed to provide targeted immunological protection against three circulating influenza strains, making it an essential component of comprehensive seasonal flu prevention programs in clinical and occupational health settings.
The trivalent formulation combines inactivated split virion technology with a carefully selected antigenic composition that aligns with seasonal epidemiological predictions. Each dose is engineered to stimulate robust humoral immune response while maintaining a favorable safety profile across diverse patient populations. The inactivated split virion preparation reduces reactogenicity compared to whole virion vaccines while preserving immunogenic potency.
Influvac is administered via intramuscular injection, typically in the deltoid muscle, with a standard dosing schedule established through rigorous clinical trials. The vaccine is suitable for annual administration as part of seasonal influenza immunization protocols in healthcare facilities, occupational health clinics, and preventive medicine programs.
This product meets international pharmacopeial standards for viral vaccine preparation and is supported by extensive clinical documentation. Healthcare professionals administering Influvac should review complete prescribing information, contraindications, and patient screening requirements prior to injection. Proper cold chain management and storage protocols are essential to maintain vaccine potency.
Influvac represents a trusted option for institutions seeking reliable, data-backed influenza immunization solutions. Consult immunization guidelines and clinical references for patient eligibility, dosing schedules, and post-vaccination monitoring recommendations.
Share
